Biofrontera Inc.
BFRI Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$0.82
KIRA · Stoqly’s AI analyst, in plain words
- Biofrontera Inc. had $41.7M of revenue in fiscal 2025, up 11.7% on the year before. Over five years, revenue changed +17.2% a year on average.
- Its operating margin was −27.2%, up 18.9 pts: of every 100 in sales, about −27 is left after running the business.
- Biofrontera Inc. lost $10.5M in fiscal 2025.
- Free cash flow was −$13.4M in fiscal 2025, −32.0% of revenue.
Market cap
$10.6M
P/E
—
Revenue
$41.7M
Net income
−$10.5M
Free cash flow
−$13.4M
Operating margin
−27.2%
Biofrontera Inc. in 30 seconds · fiscal 2025
Are sales growing?
+11.7%
Yes. Sales grew 11.7% last year.
Does it make a profit?
−25.3%
No. It lost money last year.
Does profit turn into cash?
−32.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Biofrontera Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 19, 2026
- Legal name
- Biofrontera Inc.
- CIK
- 0001858685
Biofrontera Inc. · BFRI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $24.1M | $28.7M | $34.1M | $37.3M | $41.7M |
| Revenue growth | 27.9% | 19.0% | 18.8% | 9.5% | 11.7% |
| Net interest income | −$0.3M | −$0.2M | −$0.5M | — | — |
| Operating margin | −104.6% | −64.8% | −66.6% | −46.1% | −27.2% |
| Net income | −$37.7M | −$0.6M | −$20.1M | −$17.8M | −$10.5M |
| Net margin | −156.5% | −2.2% | −59.1% | −47.6% | −25.3% |
| Diluted EPS | −$4.28 | −$0.61 | −$13.02 | −$3.22 | −$1.04 |
| Cash | |||||
| Cash from operations | −$26.7M | −$16.2M | −$24.9M | −$10.3M | −$13.4M |
| Capital expenditure | — | $0.0M | $0.0M | $0.0M | $0.0M |
| Free cash flow | — | −$16.2M | −$24.9M | −$10.3M | −$13.4M |
| FCF margin | — | −56.6% | −73.1% | −27.5% | −32.0% |
| Share count change | 38,338.7% | −100.0% | 46.3% | 256.7% | 84.4% |
| Debt and strength | |||||
| Cash and short-term investments | $24.5M | $17.2M | $1.3M | $5.9M | $6.4M |
| Debt incl. finance leases | — | — | $3.9M | — | — |
| Shareholders' equity | $11.3M | $23.9M | $4.8M | $4.4M | $10.5M |
| Current ratio | 3.4x | 2.1x | 1.3x | 1.7x | 1.5x |
| Interest coverage | −73.3x | −1,548.4x | −103.1x | — | — |
| Returns and quality | |||||
| Return on capital | — | — | −243.6% | — | — |
| Return on equity | −439.4% | −3.6% | −140.4% | −385.0% | −141.3% |
| Return on tangible equity | −478.1% | −3.1% | −930.3% | −403.8% | −134.6% |
| Piotroski F-score | 1 | 3 | 1 | 3 | 1 |
| Altman Z'' | −3.7 | −3.8 | −15.7 | −19.7 | −15.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Biofrontera Inc. · BFRI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.82 a share, the company is worth $10.6M.
Source: SEC EDGAR XBRL filings (CIK 0001858685). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.